Amgen files for U.S. approval of biosimilar to Humira

November 25, 2015 9:17 PM

24 0

Amgen files for U.S. approval of biosimilar to Humira

Amgen Inc on Wednesday said it filed with U.S. health regulators seeking approval to sell its first biosimilar drug, which would be a less expensive alternative to AbbVie's Humira, the world's top-selling prescription medicine.

Amgen said its drug, ABP 501, has demonstrated clinical equivalence and comparable safety to Humira (adalimumab) in late stage clinical trials for rheumatoid arthritis and the skin condition plaque psoriasis.

Also read: Turkey borrows $2 billion in 10-year eurobond issue, final yield 6.15 pct

Read more

To category page

Loading...